Discovery and clinical progression of highly selective M1 agonists utilizing structure-based drug design

被引：0
|
作者：
Brown, Giles [1 ]
机构：
[1] Heptares Therapeut Ltd, Cambrdige, England
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2017年 / 254卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
244
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Discovery of highly potent novel antifungal azoles by structure-based rational design
    Wang, Wenya
    Sheng, Chunquan
    Che, Xiaoying
    Ji, Haitao
    Cao, Yongbing
    Miao, Zhenyuan
    Yao, Jianzhong
    Zhang, Wannian
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (20) : 5965 - 5969
  • [42] Discovery of a highly potent, functionally-selective muscarinic M1 agonist,WAY-132983 using rational drug design and receptor modelling
    Sabb, AL
    Husbands, GM
    Tokolics, J
    Stein, RP
    Tasse, RP
    Boast, CA
    Moyer, JA
    Abou-Gharbia, M
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (14) : 1895 - 1900
  • [43] Structure-based discovery of selective BRPF1 bromodomain inhibitors
    Zhu, Jian
    Zhou, Chunxian
    Caflisch, Amedeo
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 155 : 337 - 352
  • [44] Structure-Based Drug Design of Bcl-XL Selective Inhibitors
    Judge, R.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2021, 77 : A17 - A17
  • [45] Structure-based design and discovery of potent and selective KDM5 inhibitors
    Nie, Zhe
    Shi, Lihong
    Lai, Chon
    O'Connell, Shawn M.
    Xu, Jiangchun
    Stansfield, Ryan K.
    Hosfield, David J.
    Veal, James M.
    Stafford, Jeffrey A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (09) : 1490 - 1494
  • [46] Structure-based and property-based drug design of AZD5305, a highly selective PARP1 inhibitor and trapper.
    Hande, Sudhir
    Balazs, Amber
    Degorce, Sebastien L.
    Embrey, Kevin
    Ghosh, Avipsa
    Gill, Sonja J.
    Gunnarsson, Anders
    Illuzzi, Giuditta
    Lane, Jordan
    Larner, Carrie
    Leo, Elisabetta
    Madin, Andrew
    McWilliams, Lisa
    O'Connor, Mark J.
    Orme, Jonathan
    Pachl, Fiona
    Packer, Martin
    Pike, Andy
    Rawlins, Philip
    Schimpl, Marianne
    Staniszewska, Anna D.
    Zhang, Andrew
    Zheng, Xiaolan
    Johannes, Jeffrey W.
    CANCER RESEARCH, 2021, 81 (13)
  • [47] Structure-based ligand design to overcome CYP inhibition in drug discovery projects
    Branden, Gisela
    Sjogren, Tove
    Schnecke, Volker
    Xue, Yafeng
    DRUG DISCOVERY TODAY, 2014, 19 (07) : 905 - 911
  • [48] Metamorphosis of paroxetine into a highly potent and selective GRK2 inhibitor via structure-based drug design
    Waldschmidt, Helen
    Homan, Kristoff
    Cruz-Rodriguez, Osvaldo
    Cato, Marilyn
    Bouley, Renee
    Wilson, Michael
    Cannavo, Alessandro
    Song, Jianliang
    Cheung, Joseph
    Kirchhoff, Paul
    Koch, Walter
    Tesmer, John
    Larsen, Scott
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [49] Selective muscarinic M-1 antagonists: Drug design and discovery
    Widzowski, D
    Helander, HF
    Wu, ESC
    DRUG DISCOVERY TODAY, 1997, 2 (08) : 341 - 350
  • [50] Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening
    Dighe, Satish N.
    Deora, Girdhar Singh
    De la Mora, Eugenio
    Nachon, Florian
    Chan, Stephen
    Parat, Marie-Odile
    Brazzolotto, Xavier
    Ross, Benjamin P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (16) : 7683 - 7689
12345